1360130-72-8Relevant academic research and scientific papers
Dual-acting histone deacetylase-topoisomerase i inhibitors
Guerrant, William,Patil, Vishal,Canzoneri, Joshua C.,Yao, Li-Pan,Hood, Rebecca,Oyelere, Adegboyega K.
supporting information, p. 3283 - 3287 (2013/06/27)
Current chemotherapy regimens are comprised mostly of single-target drugs which are often plagued by toxic side effects and resistance development. A pharmacological strategy for circumventing these drawbacks could involve designing multivalent ligands th
HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF
-
Page/Page column 29-30, (2012/05/04)
Compounds of Formula (I), and methods of making and using thereof, are described herein; wherein AR is an aryl group, ZBG is a Zinc Binding Group, and other substituents are as defined herein. The compounds can be administered as a pharmaceutically acceptable salt, prodrug, or solvate. The compounds may be useful to treat and/or prevent hyperproliferative disorders which may include hormone sensitive and hormone refractory prostate cancers. The compounds can be formulated with a pharmaceutically acceptable carrier and, optionally one or more pharmaceutically acceptable excipients, for enteral or parenteral administration.
